Related Experiment Video

Updated: Oct 14, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

789

The roles of exosomal immune checkpoint proteins in tumors

Cheng Xing1,2, Heng Li1,2, Rui-Juan Li1,2

  • 1Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.

Military Medical Research
|November 8, 2021
PubMed

Insights

Tumor-derived exosomes contribute to immune resistance against cancer therapies. Exosomal immune checkpoint proteins like PD-L1 and CTLA-4 are key players in this process, driving tumor progression and immune suppression.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Immune checkpoint inhibitors show promise for early-stage tumors.
  • Adaptive resistance limits the efficacy of current immunotherapies.
  • Tumor-derived exosomes are increasingly recognized for their role in immune suppression.

Purpose of the Study:

  • To highlight the role of exosomal immune checkpoint proteins in tumor immunity.
  • To emphasize the function of PD-L1 and CTLA-4 in exosome-mediated immune suppression.
  • To discuss emerging evidence on TIM-3, ARG1, and EBAG9 in exosomal immune regulation.

Main Methods:

  • Literature review and synthesis of current research.
  • Analysis of studies investigating exosomal protein expression.
  • Focus on programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

Main Results:

  • Exosomal immune checkpoint proteins, including PD-L1 and CTLA-4, are implicated in systemic immune suppression.
  • These proteins on exosomes can hinder anti-tumor immune responses.
  • Emerging data suggests TIM-3, ARG1, and EBAG9 on exosomes also modulate tumor immunity.

Conclusions:

  • Exosomal immune checkpoint proteins represent a significant mechanism of immune evasion in cancer.
  • Targeting these exosomal proteins could overcome adaptive resistance to immunotherapy.
  • Further research into exosomal proteins like TIM-3, ARG1, and EBAG9 is warranted for novel therapeutic strategies.
Keywords:
ExosomesImmune checkpointsTumor

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.7K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
731
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.0K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K